Metro Inc. — the cost of waiting for grocery traffic to recover

Our maximum entry price is C$81.67 per share. Metro closed at C$97.58 on November 18, so the base model says wait. The five-year observed market-risk estimate raises entry to C$109.88 and changes the price decision to buy. TSX daily close, Nov 18

Stock Price History

Market close (CAD)
$97.58
Bear fair value (CAD/share)
$47.83
Company details
Base fair value (CAD/share)
$94.27
Bull fair value (CAD/share)
$180.79
Maximum entry price (CAD/share)
$81.67

Only C$3.31 of the C$15.91 gap to entry comes from the DCF. The other C$12.60 comes from requiring a 9.5% annual return over five years. At the close the retained model earns 5.67%. A buyer could still meet our hurdle if diluted earnings grow 8% annually and Metro trades at about 23.7× earnings in year five. Cash reconciliation · Risk sensitivity · Market case

Stock Price History

Investment Thesis

Metro’s pharmacy business expanded as the Laval produce disruption hurt food sales. A recovery in store traffic can lift earnings, but permanent store investment and rent limit how much of that recovery reaches a share. Metro food and pharmacy sales, p. 22 · Highlighted row · Metro strike estimate and margin, p. 4

Market Mispricing

The market close is just 3.5% above our estimated fair value. The main reason to wait is the five-year upside required relative to XIC. Empirical risk estimates challenge the retained discount rate, so conviction in the wait call is limited.

Recent Developments

The six-month Laval labour conflict ended September 24. Management reports normal service levels and aims to restore traffic. Q4 food same-store sales fell 1.9%, while pharmacy comparable sales grew 5.5%. Metro operating update, p. 2

Earnings Outlook

First-year FCFF is C$886.96m and year-five FCFF C$1,027.20m. Base year one recovers one-quarter of estimated lost pretax strike profit. The adjustment is a level, not a fresh annual gain. Metro strike estimate and margin, p. 4

Valuation Summary

Ten years of cash flow plus a funded terminal period give C$94.27 per share. The prior report’s C$99.18 was a one-year forward valuation. The newly calculated C$81.67 is a maximum purchase price. Preceding November 18 structured edition

Recommended Action and Entry Price

At C$97.58, the model implies 5.67% annual shareholder return versus a 7.5% XIC assumption. At C$81.67, the same dividends and exit value meet a 9.5% annual hurdle after illustrative trading costs.

Catalysts

Q1 food traffic and comparable sales are the first recovery tests. Watch shrink, network investment, and capital spending as well as the headline EPS rebound. Metro operating update, p. 2

Primary Risks to Thesis

The largest risk to waiting is that the market reasonably discounts defensive cash flows below our 6.5% rate. Higher pharmacy growth and faster conversion savings could widen the gap further. Metro food and pharmacy sales, p. 22 · Highlighted row